pharmaceutical company in the world for seven years.
-- William Asmundson, our lead outside director, chairs the executive
sessions of the independent directors and is the intermediary between
the Board and management. Bill currently manages an investment fund and
has had a distinguished career as an investment manager, including as
CEO and Chief Investment Officer of Rockefeller & Co. and related
investment companies for 17 years.
"Datascope's Board and management are focused on achieving continued top- and bottom-line growth and creating value for all Datascope shareholders. We continue to urge all shareholders to reject Ramius' nominees and re-elect the Board's incumbent directors by voting Datascope's BLUE proxy card today."
On behalf of the Datascope Board, Mr. Klatell also commented on the Risk Metrics' ISS proxy advisory unit report, which was issued late Friday, effectively recommending a split vote at the Company's December 20th shareholder meeting.
"We think that their report fails to recognize fully the significant contributions made by both of Datascope's nominees. ISS nonetheless does acknowledge the dissident's small stake in the Company, which it only recently
accumulated. Clearly the dissident has offered no business plan or any suggestions to benefit Datascope or its shareholders."
Mr. Klatell also noted, "William Wyman, one of Datascope's independent
directors, has extensive experience in the medical industry. He has been a
trustee of the Mary Hitchcock Memorial Hospital, a 400-bed primary trauma
center, for 12 years; a trustee of The Dartmouth Clinic, a 650 doctor
entity, for six years; and a trustee of the Dartmouth Hitchcock Medical
Center (the largest academic medical center in northern New England), which
oversees and coordinates the operations of the Mary Hitchcock Memorial
Hospital, The Dartmouth Clinic, the Dartmou
|SOURCE Datascope Corp.|
Copyright©2007 PR Newswire.
All rights reserved